Chinese smartphone company Honor on Thursday announced backing from new investors as the Huawei spinoff prepares for an initial public offering.
Schlagwort-Archiv: CNBC
Sigh of relief for UK tech founders as Labour hikes capital gains tax by less than feared
Britain’s Labour government on Wednesday announced plans to raise the rate of capital gains tax on sales of shares — the move was less severe than feared.
Peloton raises its full-year profit guidance, but expects the holiday quarter to be softer than expected
Peloton’s cash flows are improving, but it’s expecting to sell fewer bikes and treadmills during its holiday quarter than Wall Street expected.
Bristol Myers Squibb tops earnings estimates and hikes outlook, helped by Eliquis and new drugs
The pharmaceutical giant also raised its full-year revenue forecast to an increase of roughly 5%.
Merck tops earnings estimates on strong demand for Keytruda, new drugs even as HPV vaccine sales fall
The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health business.
Comcast tops earnings estimates as Olympics propel the company
Comcast beat third-quarter earnings estimates as the Summer Olympics in Paris boosted NBCUniversal’s revenue and Peacock’s subscriber count.
Uber reports third-quarter results that beat Wall Street’s revenue expectations
Uber reported third-quarter results Thursday that beat analysts‘ expectations for revenue.
Wednesday’s big stock stories: What’s likely to move the market in the next trading session
The Nasdaq Composite notched a fresh record on Tuesday ahead of earnings from tech’s heavy hitters. Here’s what CNBC is watching going into Wednesday.
China’s Xiaomi delivers 20,000 EVs in October, just months after launching its first car
The Chinese smartphone company also announced a high-end sports version of the car, the SU7 Ultra, would begin preorders ahead of a product release in March.
Biogen tops estimates, raises profit guidance as Alzheimer’s drug Leqembi gains traction
Leqembi, along with rare disease and depression treatments, helped offset a year-over-year decline in revenue for the company’s multiple sclerosis products.